Suleyman Serdar Koca
Overview
Explore the profile of Suleyman Serdar Koca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Misirci S, Ekin A, Yagiz B, Coskun B, Basibuyuk F, Birlik A, et al.
Clin Rheumatol
. 2025 Feb;
44(3):1187-1195.
PMID: 39920562
Objective: The aim of this study is to assess the efficacy and safety of nintedanib (NTD) therapy in a real world population of patients with connective tissue diseases related interstitial...
2.
Baglan Yentur S, Bilek F, Deniz G, Akgol G, Koca S
J Am Podiatr Med Assoc
. 2025 Jan;
114(6.
PMID: 39874077
Background: Many factors, such as decreased spinal mobility, pain, and dysfunction can affect gait parameters in patients with ankylosing spondylitis. The purpose of this study was to investigate the effects...
3.
Aydin U, Karatas A, Artas G, Oz B, Aydogdu M, Artas H, et al.
Hum Immunol
. 2024 Dec;
86(1):111222.
PMID: 39740302
Background: Idiopathic granulomatous mastitis (IGM) is a chronic inflammatory disorder characterised by the formation of non-caseating granulomas in breast tissue, primarily affecting young women of childbearing age. The aetiology of...
4.
Uslu S, Gulle S, Sen G, Capar S, Senel S, Dalkilic E, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685726
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile....
5.
Ocak T, Yagiz B, Ocak B, Yogurtcu O, Basibuyuk F, Tezcan D, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458166
: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of...
6.
Albayrak F, Kisacik B, Gunduz I, Kudas O, Koc E, Zengin O, et al.
Clin Rheumatol
. 2024 Sep;
43(11):3345-3350.
PMID: 39285007
Objectives: Inflammatory low back pain (IBP) is a typical feature of spondylarthritis (SpA). IBP can be caused by infections, drugs, and different malignancies. Among cancers, hematologic malignancies and solid tumors...
7.
Uslu S, Gulle S, Sen G, Cefle A, Yilmaz S, Kocaer S, et al.
Sci Rep
. 2024 Jun;
14(1):14194.
PMID: 38902436
Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated...
8.
Karatas A, Sagir R, Koca S, Dalkilic E, Can G, Pehlivan Y, et al.
Turk J Med Sci
. 2024 May;
53(5):1321-1329.
PMID: 38813042
Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to...
9.
Avanoglu Guler A, Ozcimen B, Aydogdu M, Sari A, Numune A, Ersan N, et al.
Turk J Med Sci
. 2024 May;
54(1):76-85.
PMID: 38812619
Background/aim: The objective of this study is to evaluate the clinical presentations and adverse outcomes of Coronavirus Disease 2019 (COVID-19) in patients with systemic sclerosis (SSc) and assess the impact...
10.
Albayrak F, Gur M, Karatas A, Koca S, Kisacik B
Reumatol Clin (Engl Ed)
. 2024 Mar;
20(3):123-127.
PMID: 38494303
Objective: In this study, our objective was to present real-life data on the incidence of inflammatory bowel disease (IBD) among patients receiving secukinumab treatment. Methods: The study consisted of 209...